In a NASH model in rats injected with a hepatic carcinogen diethylnitrosamine (DEN, 30 mg/kg BW, i.p., once) and fed with HFD, EGCG administration (0.01% and 0.1% in drinking water) could significantly inhibit the development of GST-P-positive foci (an indicator of preneoplastic HCC lesions), with the reduction in hepatic TG level, the improvements in hepatic oxidative stress (CAT and GPX), inflammation (TNF-α, IL-6, and IL-1β), and fibrosis (TIMP-1 and TIMP-2 mRNA), and the inhibition in excessive hepatocyte proliferation (cyclin D1 mRNA) [145]. The gene discussed is CCND1; the disease is metabolic dysfunction-associated steatohepatitis.